SALESFORCE INC (CRM) 160.25 +8.57 (+5.65%)
160.25 +8.57 (+5.65%)
US79466L3024 - Common Stock - After market: 149.1 -11.15 (-6.96%)
Fundamental Rating
We assign a fundamental rating of 4 out of 10 to CRM. CRM was compared to 369 industry peers in the Software industry. Both the profitability and the financial health of CRM get a neutral evaluation. Nothing too spectacular is happening here. CRM is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
CRM's Return On Assets of 0.57% is amongst the best of the industry. CRM does better than the industry average Return On Assets of -11.76%.
CRM has a Profit Margin of 1.83%. This is better than the industry average of -22.20%.
The Piotroski-F score of CRM is 6.00. This is a neutral score and indicates average health and profitability for CRM.
CRM has a Return On Equity of 0.89%. This is below the industry average of 11.69%. 95% of the industry peers outperform CRM.
VS Industry
ROA (0.57%) VS Industry: 75% outperformed.
-1,731.36
102.42
ROE (0.89%) VS Industry: 5% outperformed.
0.28
278.50
Profit Margin (1.83%) VS Industry: 74% outperformed.
-120,709.80
941.10
Valuation
Valuation Rating
Compared to an average industry Price/Earning Ratio of 32.86, CRM is valued in line with its industry peers.
CRM's PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
When comparing the current price to the book value of CRM, we can conclude it is valued correctly. It is trading at 2.67 times its book value.
Compared to an average industry price book ratio of 2.84, CRM is valued in line with its industry peers.
With a Price/Earnings Ratio of 37.44, CRM can be considered very expensive at the moment.
With a Forward Price/Earnings Ratio of 27.94, CRM is valued very expensively.
Compared to an average industry Enterprise Value to EBITDA ratio of 15.59, CRM is valued more expensive than its industry peers.
VS Industry
Price/Earnings (37.44) VS Industry: 44% outperformed.
4,014.00
0.38
Price/Book (2.67) VS Industry: 52% outperformed.
287.27
0.10
Enterprise Value/ EBITDA (37.58) VS Industry: 22% outperformed.
1,266.93
0.06
Growth
Growth Rating
Measured over the past 5 years, CRM shows a very strong growth in Earnings Per Share. The EPS has been growing by 36.85% on average per year.
The Earnings Per Share is expected to grow by 16.69% on average over the next 5 years. This is quite good.
Looking at the last year, CRM shows a very strong growth in Revenue. The Revenue has grown by 24.56%.
Measured over the past 5 years, CRM shows a very strong growth in Revenue. The Revenue has been growing by 25.71% on average per year.
Based on estimates for the next 5 years, CRM will show a quite strong growth in Revenue. The Revenue will grow by 12.98% on average per year.
CRM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.76%.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 36.85% | 22.99% | -21.76% | -0.28% | 9.31% | 13.86% | 16.69% |
| Revenue | 25.71% | 25.88% | 24.56% | 17.39% | 16.03% | 16.25% | 12.98% |
Health
Health Rating
An Altman-Z score of 3.11 indicates that CRM is not in any danger for bankruptcy at the moment.
CRM is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 1.70.
A Current Ratio of 1.06 indicates that CRM should not have too much problems paying its short term obligations.
CRM has a Quick Ratio of 1.06. This is a normal value and indicates that CRM is financially healthy and should not expect problems in meeting its short term obligations.
CRM has a Piotroski-F score of 6.00. This indicates an average health and profitability for CRM.
Compared to an average industry Current Ratio of 1.82, CRM is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 1.80, CRM is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.04, CRM is more dependent on financing than its industry peers.
VS Industry
Debt/Equity (0.16) VS Industry: 38% outperformed.
51.02
0.00
Quick Ratio (1.06) VS Industry: 25% outperformed.
0.03
83.89
Current Ratio (1.06) VS Industry: 23% outperformed.
0.03
83.89
Altman-Z (3.11) VS Industry: 64% outperformed.
-182.70
250.30
Dividend
Dividend Rating
No dividends for CRM!.
SALESFORCE INC160.25
NYSE:CRM (11/30/2022, 5:40:29 PM)+8.57 (+5.65%)
| GICS Sector | Information Technology | ||
| GICS IndustryGroup | Software & Services | ||
| GICS Industry | Software | ||
| Earnings (Last) | 08-24 2022-08-24/amc | Earnings (Next) | 11-30 2022-11-30/amc |
| Ins Owners | 2.91% | Inst Owners | 77.25% |
| Market Cap | 160.25B | Analysts | 81.85 |
| PE | 37.44 | Fwd PE | 27.94 |
| PEG (NY) | N/A | PEG (5Y) | 1.02 |
| P/S | 5.47 | P/B | 2.67 |
| EV/EBITDA | 37.58 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -21.76% | EPS 3Y | 22.99% |
| EPS 5Y | 36.85% | EPS growth Q2Q | -19.59% |
| EPS Next Y | -0.28% | EPS Next 2Y | 9.31% |
| EPS Next 3Y | 13.86% | EPS Next 5Y | 16.69% |
| Revenue growth 1Y | 24.56% | Revenue growth 3Y | 25.88% |
| Revenue growth 5Y | 25.71% | Revenue growth Q2Q | 21.77% |
| Revenue Next Year | 17.39% | Revenue Next 2Y | 16.03% |
| Revenue Next 3Y | 16.25% | Revenue Next 5Y | 12.98% |
| Current Ratio | 1.06 | Quick Ratio | 1.06 |
| Altman-Z | 3.11 | F-Score | 6 |
| Debt/Equity | 0.16 | WACC | 10.67% |
| ROIC/WACC | 0.17 | ||
| ROA | 0.57% | ROE | 0.89% |
| ROICexgc | 1.81% | ROIC | 0.1% |
| PM | 1.83% | OM | 0.26% |
| Asset Turnover | 0.31 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA